キングス・カレッジ・ロンドンによる新たな研究によると、関節リウマチ発症のハイリスク者に対し、アバタセプトを1年間投与することで、発症を最大4年遅らせることが可能であることがわかりました。この効果は、治療終了後も長期にわたり持続しました。
医学誌「ランセット・リウマチ学（The Lancet Rheumatology）」に掲載されたこの研究では、先行試験の参加者を4年から8年にわたって追跡調査しました。研究チームは、関節リウマチの発症リスクが高い英国とオランダの計213名を対象に追跡を行いました。その結果、アバタセプトの投与を受けたグループは、プラセボ群と比較して発症時期が大幅に遅れ、治療期間終了後も数年にわたって発症が抑制されるケースが確認されました。
AIによるレポート AIによって生成された画像 事実確認済み
A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.
Researchers at the University of Colorado Boulder have demonstrated that a single injected drug-delivery system can reverse osteoarthritis in animals within weeks. The team, led by chemical and biological engineer Stephanie Bryant, reported success in early animal experiments. They aim to advance to human trials after further safety testing.
AIによるレポート
Promising animal studies from University of Colorado Boulder offer hope for osteoarthritis patients through a single injection that repairs damaged joints in weeks. Affecting one in six people over 30—with no cure—the disease limits daily activities, but this therapy targets root causes beyond pain management or surgery.
Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.
AIによるレポート
A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.